The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 06, 2014
Filed:
May. 21, 2010
Matthew Baker, Cambridge, GB;
Francis J. Carr, Aberdeenshire, GB;
Koen Hellendoorn, Suffolk, GB;
Jeannick Cizeau, Manitoba, CA;
Glen Christopher Macdonald, Manitoba, CA;
Joycelyn Entwistle, Manitoba, CA;
Denis Georges Bosc, Manitoba, CA;
Nicholas Ronald Glover, Ontario, CA;
Matthew Baker, Cambridge, GB;
Francis J. Carr, Aberdeenshire, GB;
Koen Hellendoorn, Suffolk, GB;
Jeannick Cizeau, Manitoba, CA;
Glen Christopher MacDonald, Manitoba, CA;
Joycelyn Entwistle, Manitoba, CA;
Denis Georges Bosc, Manitoba, CA;
Nicholas Ronald Glover, Ontario, CA;
Merck Patent GmbH, Darmstadt, DE;
Abstract
The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.